RUNX1 and acute myeloid leukemia: For example, patients with genomic translocations such as t(15;17) (lead to PML–RARa fusion protein), t(8;21) (lead to AML1–ETO fusion protein) and inv(16) (lead to CBFb–MYH11 fusion protein) were classified in the favorable-risk group, cytogenetically normal AML (CN-AML) were in the intermediate-risk group, and those with a complex karyotype were classified in the adverse-risk group [6].